MIFH
PLX icon

Migdal Insurance & Financial Holdings’s Protalix BioTherapeutics PLX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,432
Closed -$2K – 671
2021
Q4 		$2K Sell
2,432
-1,568
-39% -$1.64K ﹤0.01% 668
2021
Q3 		$5K Buy
+4,000
New +$6.08K ﹤0.01% 634

Other funds holding PLX

PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
SFI
Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return

Migdal Insurance & Financial Holdings's PLX Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Protalix BioTherapeutics (PLX) in Q1 2022, closing a stake of 2,432 shares — an estimated $2K sold.

Migdal Insurance & Financial Holdings first reported a position in PLX in Q3 2021 and held it in 2 quarters. The position peaked at $5K in Q3 2021. 32 funds tracked by Wall St. Rank hold PLX as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Protalix BioTherapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 2,432 Protalix BioTherapeutics shares in Q1 2022, an estimated $2K.
  • Migdal Insurance & Financial Holdings first reported a position in Protalix BioTherapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Protalix BioTherapeutics position peaked at $5K in Q3 2021.
  • 32 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.